Medical Technologies Leader Cellmyx Announces U.S. Food and Drug Administration (FDA) 510(k) Clearance for intelliFat® BODtm (Ref.# K210528) ISO 13485#0136711 and MDSAP#0136710 Certification

The most advanced, quickest and easiest, single-use kit for macro, micro, and nano fat tissue harvesting, processing, and transfer. 

CARLSBAD, Calif., Jan. 10, 2023 /PRNewswire/ -- Our company has now completed the certification process for our ISO 13485 #013671 and MDSAP #0136710, these certificates will allow Cellmyx to expand our distribution efforts worldwide. Cellmyx, one of the authorities on autologous adipose grafting and transfer, a leader in medical technologies for orthopedic physicians, pain management, and regenerative medicine, announces U.S. Food and Drug Administration (FDA) 510(k) clearance for intelliFat® BODtm (Ref.# K210528). The most advanced, quickest and easiest, single use kit for macro, micro, and nano fat tissue harvesting, processing, and transfer.

U.S. regulators have cleared the way for this groundbreaking new medical appliance and technology for use in orthopedic, plastic, and cosmetic surgery procedures. intelliFat® BODtm successfully uses a patient's own body fat, clinically referred to as adipose tissue, to aid in patient recovery and healing. In some cases, intelliFat® BODtm is used in conjunction with traditional orthopedic surgery to further advance patient outcomes. intelliFat® BODtm is particularly attractive to physicians because it's compliant with the latest FDA guidelines, preserving cellular and tissue micro-architecture of adipose, eliminating residual oil emulsion and blood, thereby providing a tissue byproduct that is minimally manipulated in accordance with FDA guidelines for Human Cell and Tissue Products.

Kits are sterile, and disposable, and contain a full suite of proprietary and stand-alone components to harvest, process, and transfer autologous adipose tissue for use as an alternative, and/or as an adjunct, to surgery for filling soft tissue defects and promoting healing in orthopedics, plastic, and cosmetic surgery, and a multitude of other surgical procedures and specialties.

Physicians feel empowered. They have the assets they need right at their fingertips to perform this revolutionary procedure without incising, stitching, or scarring the patient. intelliFat® BODtm streamlines procedure times to under 30 minutes with its patented and unparalleled harvesting, processing, and transfer system. Patients experience no discomfort or downtime during or post-procedure and may return to normal social activities immediately with clearance from their provider.

According to Associate Clinical Professor of Medicine, University of Connecticut School of Medicine, Fellow of the American Osteopathic Academy of Sports Medicine, and Board Certified in Sports Medicine & Regenerative Medicine Dr. Paul D. Tortland, D.O. FAOASM, RSMK: 

"I began performing autologous fat derived treatments for orthopedic regenerative medicine in 2009, the first physician in New England, and among the earliest in the country. Over the years I've trialed most commercially available systems to harvest and prepare adipose for injection. I have found these systems are cumbersome to use, time-consuming, or produce suboptimal product for injection. But with intelliFat® BODtm Cellmyx hit the mark. Their kit is elegantly simple, fast and easy to use, and produces a superlative final product that's easy to inject. Most importantly, I'm seeing outstanding clinical results."

The intelliFat® BODtm 510(k) specifically includes procedures for neurosurgery, gastrointestinal and affiliated organ surgery, urological surgery, plastic, cosmetic, and reconstructive surgery, general surgery, orthopedic surgery, gynecological surgery, laparoscopic surgery, arthroscopic surgery, and thoracic surgery.

About Cellmyx:

Millennium Medical Technologies, Inc. DBA Cellmyx is a U.S. Food and Drug Administration (FDA) registered manufacturer committed to providing comprehensive solutions and support for harvesting, isolation, and deployment of PHSA 361 compliant tissue and cells. Cellmyx is committed to advancing the art of cosmetic surgery and regenerative medicine and continues to explore and develop novel concepts to enhance their proprietary product portfolio bringing physicians the most advanced technology in adipose tissue transfer.

Media Contact:
Greg Miles, CEO and Founder
1-949-215-8560

SOURCE Cellmyx